JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

Human pancreatic cancer does not respond to immune check point blockade immunotherapy. One key feature of pancreatic cancer is the association between its progression and chronic inflammation. Emerging evidence supports a key role for the JAK-STAT pathway in pancreatic cancer inflammation. We aimed...

Full description

Bibliographic Details
Main Authors:	Chunwan Lu, Asif Talukder, Natasha M. Savage, Nagendra Singh, Kebin Liu
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2017-03-01
Series:	OncoImmunology
Subjects:	cytotoxic t lymphocytes fasl pd-1 pd-l1 ruxolitinib stat1 stat3
Online Access:	http://dx.doi.org/10.1080/2162402X.2017.1291106

Similar Items

STAT4 facilitates PD‐L1 level via IL‐12R/JAK2/STAT3 axis and predicts immunotherapy response in breast cancer
by: Jianbo Zhou, et al.
Published: (2023-12-01)

The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1
by: Nofar Erlichman, et al.
Published: (2023-09-01)

JAK-STAT1 Signaling Pathway Is an Early Response to <em>Helicobacter pylori</em> Infection and Contributes to Immune Escape and Gastric Carcinogenesis
by: Xue Li, et al.
Published: (2022-04-01)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
by: Dinoop Ravindran Menon, et al.
Published: (2021-10-01)

PYCR1 promotes the malignant progression of lung cancer through the JAK-STAT3 signaling pathway via PRODH-dependent glutamine synthesize
by: Lihong Zhang, et al.
Published: (2023-06-01)

Immunoprofiling of monocytes in STAT1 gain-of-function chronic mucocutaneous candidiasis
by: Marketa Bloomfield, et al.
Published: (2022-09-01)

Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway
by: Shin-Yi Chung, et al.
Published: (2021-07-01)

SPIB Knockdown Inhibits the Immune Escape of Ovarian Cancer Cells by Reducing PD-L1 (CD274) Expression and Inactivating the JAK/STAT Pathway
by: Wenfei Gu, et al.
Published: (2023-09-01)

Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway
by: Mingjing Shen, et al.
Published: (2019-04-01)

Dihydropyridine Calcium Channel Blockers Suppress the Transcription of PD-L1 by Inhibiting the Activation of STAT1
by: Xiaohui Pan, et al.
Published: (2021-01-01)

AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway
by: Wei-Min Chang, et al.
Published: (2019-06-01)

Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation
by: Ioana I. Nitulescu, et al.
Published: (2017-12-01)

SH003 overcomes drug resistance and immune checkpoints by inhibiting JAK-STAT3 signaling in MCF7/ADR cells
by: Jin Mo Ku, et al.
Published: (2021-11-01)

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
by: Angel Garcia-Diaz, et al.
Published: (2017-05-01)

Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
by: Fan Luo, et al.
Published: (2019-09-01)

Prognostic values and clinical implications of programmed cell death-ligand 1 (PD-L1), fork head transcription factor P-1 (FOXP-1) and signal transducer and activator of transcription-3 (STAT-3) expression in diffuse large B-cell lymphoma (DLBCL); an immunohistochemical study
by: Ola A. Harb, et al.
Published: (2019-06-01)

HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma
by: Hongxia Cheng, et al.
Published: (2023-12-01)

JAK Inhibitors and Oxidative Stress Control
by: Amandine Charras, et al.
Published: (2019-12-01)

Tumor associated neutrophils governs tumor progression through an IL-10/STAT3/PD-L1 feedback signaling loop in lung cancer
by: Shuai Zhang, et al.
Published: (2024-02-01)

Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy
by: Marice B. Alcantara, et al.
Published: (2024-01-01)

Inhibition of STAT3/PD-L1 and Activation of miR193a-5p Are Critically Involved in Apoptotic Effect of Compound K in Prostate Cancer Cells
by: Jae-Hee Lee, et al.
Published: (2021-08-01)

Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma
by: Lili Huang, et al.
Published: (2021-04-01)

The Interplay of Notch Signaling and STAT3 in TLR-Activated Human Primary Monocytes
by: Dagmar Hildebrand, et al.
Published: (2018-07-01)

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
by: Lu Xu, et al.
Published: (2018-10-01)

Irradiation Suppresses IFNγ-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8<sup>+</sup> T Cells Cytotoxicity
by: Chun-I. Wang, et al.
Published: (2021-09-01)

Modulation of STAT-1, STAT-3, and STAT-6 activities in THP-1 derived macrophages infected with two Trypanosoma cruzi strains
by: Melissa Martins Oliveira, et al.
Published: (2022-10-01)

Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis in rabbit
by: Xilan Yang, et al.
Published: (2020-03-01)

Butein suppresses PD-L1 expression via downregulating STAT1 in non-small cell lung cancer
by: Lin Zhao, et al.
Published: (2023-01-01)

MET Receptor Tyrosine Kinase Inhibition Reduces Interferon-Gamma (IFN-γ)-Stimulated PD-L1 Expression through the STAT3 Pathway in Melanoma Cells
by: Kyu Young Song, et al.
Published: (2023-06-01)

The role of the interferon/JAK-STAT axis in driving islet HLA-I hyperexpression in type 1 diabetes
by: Mark A. Russell, et al.
Published: (2023-10-01)

AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3
by: Hua Ye, et al.
Published: (2023-12-01)

Phosphorylated Forms of STAT1, STAT3 and STAT5 Are Expressed in Proliferating but Not Involuted Infantile Hemangioma
by: Lucy Sulzberger, et al.
Published: (2018-04-01)

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
by: Camille Keenan, et al.
Published: (2021-02-01)

Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma
by: Hyun Jung Kwon, et al.
Published: (2018-11-01)

A Broad-Based Characterization of a Cell-Penetrating, Single Domain Camelid Bi-Specific Antibody Monomer That Targets STAT3 and KRAS Dependent Cancers
by: Sunanda Singh, et al.
Published: (2022-07-01)

CHARACTERISTICS OF SIGNALING PATHWAYS MEDIATING A CYTOTOXIC EFFECT OF DENDRITIC CELLS UPON ACTIVATED Т LYMPHOCYTES AND NK CELLS
by: T. V. Tyrinova, et al.
Published: (2014-07-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

The IL‐27/IL‐27R axis is altered in CD4+ and CD8+ T lymphocytes from multiple sclerosis patients
by: Marie‐Laure Clénet, et al.
Published: (2021-01-01)

STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
by: Ioannis Zerdes, et al.
Published: (2019-10-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)